Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer.
Overview
In the US Cell & Gene (CGT) Marketplace, the payer is not only our Commercial and Government Health Plans, but also the Formulary Decision Makers within our Authorized Treatment Centers (ATCs) who are evaluating the financial viability of our therapies against all other Cell & Gene therapies (CGTs). Iovance is seeking Health Economic Value Access and Strategy (HEVAS) Director as a part of the US Market Access function to develop and translate economic evidence into value-based messaging and wi... Click Apply to read the full job description.